The LumiraDx SARS-CoV-2 Ag Ultra Test. Credit: LumiraDx / PRNewswire.

Point of care diagnostics company LumiraDx has announced that it has secured CE marking for its SARS-CoV-2 Ag Ultra Test.

Based on the company’s microfluidic immunofluorescence technology, the test is said to deliver digital and connected results in five minutes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This helps users to complete up to 80 SARS-CoV-2 Antigen tests in an eight-hour day, facilitating diagnosis and subsequent treatment of patients.

The SARS-CoV-2 Ag Ultra Test can be stored at room temperatures and is available on the same point of care (POC) Platform as LumiraDx’s high sensitivity SARS-CoV-2 Antigen, SARS-CoV-2 Antibody, Flu A/B and SARS-CoV-2 Antigen Pool tests.

LumiraDx CEO Ron Zwanziger said: “Our SARS-CoV-2 Ag Ultra Test exemplifies our mission to increase access to testing and provide rapid diagnostics without sacrificing accuracy.

“Now, clinicians, pharmacies and other providers can use a single platform and significantly increase throughput, making a profound impact on patient workflow supported by our platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This innovation and advancement of our Microfluidic technology can also be applied to other tests on our platform, which we look forward to rolling out in the coming year.”

In clinical studies, the LumiraDx SARS-CoV-2 Ag Ultra Test had 92.7% positive agreement against RT-PCR in samples collected from symptomatic individuals. The results are based on clinical data procured up to and including 12 days since the onset of first symptoms.

The test also demonstrated 95.7% positive agreement versus RT-PCR in test samples collected from asymptomatic individuals.

Based in the UK, LumiraDx focuses on commercialising a diagnostic platform that supports an array of tests.

In January, the company announced that its LumiraDx SARS-CoV-2 Antigen test can identify the Omicron variant.